Kornimate/medical-research-clean huggingface dataset:
ms versus nice for colorectal lesions

Conditions: Colorectal Neoplasms; Colorectal Polyp

Summary: objective: our study aimed to compare a recently-developed endoscopic classification with an established one for colorectal lesions in a randomised trial between 2013 and 2015.

objective: current practice requires histopathological assessment to confirm diagnosis for colorectal lesions detected at colonoscopy. advances in endoscopic imaging contribute for real-time diagnosis which, apart from being cost and time-saving, also guides decision-making and reduces risks. our study aimed to compare a recently-developed endoscopic classification with an established one. design: the modified sano's classification (ms) was compared to the narrow band imaging (nbi) international colorectal endoscopic classification (nice) in a randomised trial between 2013 and 2015. an experimented endoscopist classified each polyp, what was compared to histopathology.

Eligibility criteria:
inclusion criteria: * patients admitted in the endoscopy unit for a colonoscopy * patients over 18 years-old * patients or their caregivers that have understanding of the procedure and that have signed the consent form for the study exclusion criteria: * patients without colorectal polyps * patients with poor bowel preparation * patients that do not agree with or withdraw the consent form

Keywords: colorectal polyp colorectal lesion modified sano's classification nice classification nbi pivi guidelines ssa/p sessile serrated adenoma sessile serrated polyp
effects of transcranial direct current stimulation on fine motor skills in parkinson's disease: a pilot study

Conditions: Parkinson's Disease; Transcranial Direct Current Stimulation; Fine Motor Skills; Handwriting

Summary: the purpose of this pilot study is to determine the effect of transcranial direct current stimulation (tdcs) on brain activity and fine motor skills in patients with parkinson's disease compared to healthy controls.

the pilot study will involve a double-blind, sham controlled cross-over design where participants will receive anodal and sham tdcs stimulation in a randomized order. differences in brain activity and fine motor skill performance between groups and after tdcs stimulation will be compared.

Eligibility criteria:
inclusion criteria: * diagnosed with idiopathic pd, according to the uk brain bank criteria * hoehn and yahr (h\&y) stage ii in the 'on'-phase of the medication cycle * right dominant pd exclusion criteria: * cognitive impairment (mmse \< 23) * visuo-spatial deficits (measured by the rey-osterrieth complex figure (rocf) test) * left-handedness (evaluated by the edinburgh handedness scale) * depression * pregnancy * alcohol abuse * aneurysm clips * pacemaker * neurostimulator * implemented defibrillator * magnetically activated implant or device * implemented pump * spinal cord simulator * implemented hearing aid * artificial or prosthetic limb * metal parts in the body * any external or internal metal * artificial heart valve * other implants * history of brain surgery * migraine * family history of epilepsy * other contra-indications for tdcs and transcranial magnetic stimulation (tms) * other neurological, psychiatric or interfering upper limb problems
dual-energy computed tomography for improving imaging assessment of multiple myeloma

Conditions: Myeloma

Summary: up to 30% of patients with newly diagnosed/suspected myeloma cannot undergo or do not tolerate whole body mri (wb-mri). a number of factors may be contributory. first, wb-mri protocols can take in excess of 1 hour. patients must remain still within a narrow bore scanner with multiple mri coils that can be claustrophobic. second, there is significant acoustic noise that can be heard despite the use of ear protection. third, 80% of patients will experience bone pain or fracture at some point during their illness, affecting their comfort within the scanner. fourth, patients also have higher anxiety. one review reported up to 30% of patients experienced considerable apprehension and up to 10% severe psychological distress when undergoing mri. finally, myeloma is predominantly an illness of the elderly and co-morbid conditions decrease patients' ability to tolerate a long scan. when wb-mri cannot be performed, nice recommend whole-body computed tomography (wb-ct), which the investigators know offers decreased diagnostic performance in terms of marrow assessment and focal lesion detection. the investigators believe that using a novel ct technique - dual-energy ct (dect) - may offer better diagnostic performance over standard wb-ct in myeloma patients. what the investigators seek to do in this study is to evaluate the sensitivity and specificity of dect in a cohort of untreated patients; and compare the performance of dect to simulated standard ct (data simulated from the dect) and also to wb-mri (reference standard alongside bone marrow biopsy results. the investigators will assess both subjective visual analysis of dect images as well as ct quantitative values for the bone marrow. secondary objectives include assessment of patient experience across both imaging tests and assessment of intra \& inter observer variability in subjective visual analysis


Eligibility criteria:
inclusion criteria: * adults with suspected or newly diagnosed myeloma exclusion criteria: * no previous treatment for myeloma * no concurrent cancer elsewhere * no contraindications to ct or mri scans * routine, standard of care cut-off for minimum renal function (egfr \> 40 ml/min/1.73 m2) in order to receive iv gadolinium-based contrast media.
improving the accuracy of referrals of patients with chest pain

Conditions: Chest Pain; Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia; Heart Attack

Summary: this is a multicenter, prospective, investigator-initiated, randomized controlled trial aiming to reduce the percentage of non-cardiac chest pain (nccp) patients admitted to the cardiac emergency department (ed) by performing the modified heart score by emergency medical transport (emt) personnel.

patients with acute coronary syndrome (acs) should be referred to the hospital promptly. however, referring all patients with chest pain is not feasible, as recent studies showed that up to 80% of the patients with acute chest pain do not have acs. bedside point-of-care (poc) high sensitive troponin testing (in fingerprick blood/capillary blood) and the modified heart score have become available and might play a substantial role in the triage and diagnosis of chest pain patients in a pre-hospital setting by general practitioners (gps) and emt personnel in the future. we hypothesize that patients with chest pain can be referred more accurately by using the modified heart score.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * chest pain or other complaints suspect of acs for at least 2 hours where the gp or emergency medical personnel are in need of further diagnostics or risk stratification to come to a decision of referral. * patients, who have been informed of the nature of the study, agree to its provisions and have provided written informed consent. exclusion criteria: * electrocardiographic st-segment elevation/high suspicion of ste-acs. * suspicion of an acute non-coronary diagnosis e.g. pulmonary embolism, thoracic aortic dissection or other life-threatening disease. * patients presenting cardiogenic shock, defined as: systolic blood pressure \ 100 and peripheral oxygen saturation \<90% (without oxygen administration) * patients presenting with sudden onset heart rhythm disorders and second or third degree atrioventricular block. * patients with confirmed acs, pci or cabg \<30 days prior to inclusion. * impaired consciousness defined as an emv \<8. * severe shortness of breath. * patients with known end-stage renal disease (dialysis and/or mdrd \< 30 ml/min). * patients with known cognitive impairment. * communication issues with patient/language barrier. * patients already participating in an interventional cardiology or cardiovascular trial.

Keywords: modified heart score point-of-care testing troponin siemens healthineers
a research study on the effects of nnc0537-1482 in healthy individuals when injected under the skin

Conditions: Healthy Volunteers; Heart Failure

Summary: the study is testing a new medicine to potentially treat people with heart failure. the main purpose of the study is to see if the new study medicine is safe and how it works in the body. it is the first time nnc0537-1482 (the new study medicine) is tested in humans and will be tested in healthy individuals (men and postmenopausal women). participant will either get nnc0537-1482 or placebo (a "dummy medicine" without any active ingredients). which treatment the participant get is decided by chance and the participant will only get either the study medicine or placebo on one occasion. it will be injected under the skin of the stomach by the study staff and the number of injections will depend on the cohort participant is assigned to. nnc0537-1482 cannot be prescribed by doctors. the study consists of 6 cohorts (groups) with 6 different dosing levels. the study will last for about 9 months. participation in the study will last up to 42 days (depending on the cohort participant are assigned to) with an additional screening period that can be up to 28 days. participant will have up to 10 visits to the clinic during the study period. however, the total number of visits depend on which cohort participant is assigned to.


Eligibility criteria:
inclusion criteria: * male or postmenopausal female. * age 22-55 years (both inclusive) at the time of signing the informed consent. * body mass index (bmi) between 18.5 and 30.0 kilogram/meter per square (kg/m\^2) (both inclusive) at screening. * considered eligible and generally healthy based on the medical history, physical examination, and the results of vital signs, electrocardiogram and clinical laboratory tests performed during the screening visit, as judged by the investigator. exclusion criteria: * known or suspected hypersensitivity to study intervention(s) or related products. * use of prescription or non-prescription medicinal products, including herbal medications, within 14 days before screening. occasional use of over-the-counter vitamins, or paracetamol or non-steroidal anti-inflammatory drugs (nsaids) at their labelled doses for mild pain is permitted. * any condition which in the investigator's opinion might jeopardise participant's safety or compliance with the protocol. * orthostatic hypotension, defined as a decrease in systolic blood pressure greater than or equal to 20 millimetres of mercury (mmhg) or a decrease in diastolic blood pressure greater than or equal to 10 (mmhg) from supine to standing after 3 minutes, at the screening visit. * any laboratory safety parameters at screening outside the below laboratory ranges for: * alanine aminotransferase (alt) greater than (\>) upper normal limits (unl) plus (+) 10 percentage (%) * aspartate aminotransferase (ast) \> upper limit normal (uln) +20% * bilirubin \> uln + 20% * creatinine \> uln + 10%
a brief family-centered care program for bipolar disorder

Conditions: Bipolar Disorder

Summary: family interventions have been emphasized in the treatment of bpd and have benefits for patients' symptoms and health; however, the effects of family interventions on family function and caregivers' health-related outcomes have not been well investigated. this randomized controlled trial with 47 hospitalized patient-with-bpd/family-caregiver dyads at a medical center in northern taiwan compared the effects of a brief family-centered care (bfcc) program with treatment-as-usual (tau). the findings support both the feasibility of using the bfcc program for inpatients and its specific benefits for family function. an intensive family intervention during hospitalization has been suggested in psychiatric practice to support patients with bpd and family caregivers.

all of the family caregivers in two groups were invited to attend a routine 60-minute family discussion group about violence and suicide prevention. the tau group without specific family interview for patient and family caregiver dyad. in the bfcc group, four 90-minute bfcc program sessions were additionally provided twice a week for each hospitalized family dyad. it was hypothesized that family caregivers in the bfcc group could primary increase their family function, and secondary improve perceived health status and reduce caregiver's burdens compared to the tau. the results showed family caregivers in the bfcc group significant time group interaction effects in overall family function (p=0.03) and subscale-conflict (p=0.04), communication (p=0.01), and problem solving (p=0.04), but there were no significant interaction effects on the caregivers' perceived health status and caregiver's burdens.

Eligibility criteria:
inclusion criteria: * patients were enrolled if they met the diagnostic and statistical manual of mental disorders, 4th edition (dsm-iv) (american psychiatric association 1994) criteria for bp-i or bp-ii disorder, were able to be interviewed, and had a hamilton depression rating scale (hdrs) score \< 17 and a young mania rating scale (ymrs) score \< 38 (keck 2004) to prevent adverse effects caused by patients' mood instability. * family caregivers who were identified as: (i) significant in the patient's life, (ii) at least 18 years old, (iii) having lived with the patient for at least 6 months, (iv) able to speak and understand chinese or taiwanese, and (v) able to answer questionnaires written in chinese were included. exclusion criteria: * patients who had lived alone or lived with their family for less than 6 months, had been concurrently diagnosed with intellectual disability (dsm-5) (american psychiatric association 2013), had been newly diagnosed with bpd at this admission, or could not speak chinese were excluded. * caregivers diagnosed with a serious mental illness or intellectual disabilities were excluded.
establishment of scoring model for early and differential diagnosis of intrahepatic cholangiocarcinoma

Conditions: Intrahepatic Cholangiocarcinoma

Summary: the purpose of this study is to develop and validate a radiological nomogram including radiological characteristics, clinical risk factors, and medical history. and we aim to establish a noninvasive method for the diagnosis of intrahepatic cholangiocarcinoma (icc), and to construct a differential diagnosis model for icc and hepatocellular carcinoma (hcc) with higher sensitivity and accuracy.

in recent years, the incidence and mortality of intrahepatic cholangiocarcinoma (icc) have been increasing worldwide. due to the different treatment options for hepatocellular carcinoma (hcc) and icc, accurate differential diagnosis is critical for subsequent treatment of patients. however, because of their similar ct image enhancement patterns, they are easily misdiagnosed by clinicians, leading to an incorrect treatment. based on the above research background, our objective is to establish a noninvasive method for the diagnosis of icc and and to construct a differential diagnosis model for icc and hcc with higher sensitivity and accuracy.

Eligibility criteria:
inclusion criteria: 1. patients with pathological confirmation of icc or hcc, 2. ct was performed less than 15 days before surgery, 3. patients with complete clinical data. exclusion criteria: 1. history of other tumors, 2. metastatic liver cancer, 3. patients received preoperative chemotherapy or radiotherapy, 4. image quality analysis is not ideal.

Keywords: intrahepatic cholangiocarcinoma hepatocellular carcinoma radiomics nomogram
physical performance and 3d shoulder kinematics of asymptomatic unilateral/bilateral overhead athletes and non-athletes

Conditions: Shoulder Pain

Summary: this study compares the performance and 3-dimensional shoulder kinematics between sides in unilateral overhead-throwers (volleyball attackers), bilateral overhead athletes (swimmers) and non-athletes during two physical performance measures of the upper extremity, one in an open kinetic chain position (unilateral seated shot put test) and the other in a closed kinetic chain position (upper quarter y balance test)

3-dimensional shoulder kinematics (e.g., scapular angular position/displacement) at key events of each test will be described and compared across sides and groups. for the unilateral seated shot put test, the events are based on humeral motion: a) initiation of humeral motion, b) maximal humeral flexion, c) end of humeral motion. for the upper quarter y balance test the events are the a) initiation of free hand motion on "go", b) maximal reach on the medial direction, c) maximal reach on superolateral direction, and d) maximal reach on the inferolateral direction (kinematics measured on the stance upper extremity). the best of 3 maximal-effort trials on each side will be used for analysis. warm-up exercises and two submaximal practice trials will be performed for preparation for maximal efforts and familiarization with the tests. a rest period of at least one minute between trials will be given to guarantee good physiological conditions to maximally perform. further resting time will be allowed, if necessary, upon request of the participant.

Eligibility criteria:
inclusion criteria: * perform at least 150 degrees of arm elevation exclusion criteria: * history of shoulder dislocation * surgery in the upper extremity ≥ 6 months * injury in the past month * evident abnormalities in posture and movement of the upper body quadrant * pain at the time of testing
study of biostate® in children with hemophilia a

Conditions: Hemophilia A

Summary: the objective of this study is to assess the efficacy and safety of a von willebrand factor/factor viii (vwf/fviii), biostate, and to investigate the pharmacokinetics of biostate in children with haemophilia a.


Eligibility criteria:
inclusion criteria: * male subjects between 0 and \<12 years of age. * diagnosed with severe haemophilia a (fviii:c \<1%), and pre-treated for a minimum of 20 to 50 exposure days. * have evidence of vaccination against hepatitis a and b (or presence of antibodies against hepatitis a and b due to either a previous infection or prior immunisation), as documented in the medical notes at enrolment. * the subject and/or legal guardian understand(s) the nature of the study and has/have given written informed consent to participate in the study and is/are willing to comply with the protocol. exclusion criteria: * for all subjects at day 1: are actively bleeding. * have received an infusion of any fviii product, cryoprecipitate, whole blood, plasma or desmopressin acetate in the 4 days prior to their dosing within the pk component. * have a known history of, or who are suspected of having fviii inhibitors. * have received aspirin or other non-steroidal anti-inflammatory drugs (nsaids) within 7 days of administration of the imp. * have an impaired liver function ie, bilirubin \>1.5 x upper limit of normal (uln) and/or aspartate/alanine aminotransferase (ast/alt) \>2.5 x uln (referring to limits of the laboratory that performs the determination) at screening. * are human immunodeficiency virus \[hiv\]-1/-2 antibody positive with a viral load of \>200/µl. * suffer from an acute or chronic medical condition, other than haemophilia a, which may, in the opinion of the investigator, affect the conduct of the study. * suffering from von willebrand disease (vwd) with von willebrand factor: ristocetin cofactor (vwf:rco) level \<50 iu/dl at screening. * have a known or suspected hypersensitivity or previous evidence of severe side effects to a plasma-derived fviii product or to human albumin. * have participated in a clinical study or used an investigational compound in another study (eg, a new chemical entity not registered for clinical use) in the 3 months preceding the first day of imp administration, or are planning to enter such a study during the study period. * unwillingness and/or inability to comply with the study requirements.

Keywords: hemophilia a children
neuropsychiatry and cognition in sca3/mjd

Conditions: Spinocerebellar Ataxia Type 3; Machado-Joseph Disease; SCA3; MJD

Summary: this research investigates how cognitive-affective aspects evolve during the course of sca3/mjd. due to covid-19 pandemics, this study protocol was adapted for online-only consultations. evaluations happening after march 2020 have been done by videocall with patients, and no neurological evaluation was thus performed on these patients. a scale on activities of daily living was added to the online protocol to replace sara, scafi and ccfs scales.

by the end of this study, the evaluated population will be composed of 144 participants: 36 ataxic sca3/mjd carriers, 72 at 50% risk of carrying the sca3/mjd mutation and 36 healthy controls. ataxic subjects are invited to participate if they have an established molecular diagnosis of sca3/mjd and have a sara score greater than 2.5 points. at risk subjects are composed by the offspring of molecularly diagnosed sca3/mjd subjects that have a sara\<3. healthy controls belonging either to families living with the disease or to the general population are invited to participate according to how well they match with ataxic subjects included in the study. subjects are invited to participate in the study and, after constentment procedures, cognitive-affective assessments and a scale on activities of daily living (adl) are performed on a videocall. at risk subjects collect a blood sample for double bilnd determination of their carrier status. before march 2020, all procedures were performed in person and, instead of adl, sara, scafi and ccfs were obtained.

Eligibility criteria:
inclusion criteria: * symptomatic: * older than 18 year old; * molecular diagnosis of sca3/mjd; * sara\>2.5. * at 50% risk: * older than 18 year old; * have a parent with molecular diagnosis of sca3/mjd; * sara\<3. * healthy controls * older than 18 year old; * no genetic relationship with a sca3/mjd carrier. exclusion criteria: * non agreement in signing the informed consent; * healthy controls: having any history of genetic disorders in their families or any psychiatric or neurologic disorder.
frozen embryo transfer (fet) in natural cycles or in natural cycles controlled by human chorionic gonadotropin (hcg) administration

Conditions: Infertility

Summary: the rational of the study is to assess the implantation, pregnancy and live birth rates after the transfer of frozen- thawed embryos in natural cycles with spontaneous luteinizing hormone (lh)/progesterone rise or in natural cycles controlled by human chorionic gonadotropin (hcg) for final oocyte maturation and ovulation.


Eligibility criteria:
inclusion criteria: * age \<40 * bmi:18-29kg/m2 * day 3 embryo transfers * previously ivf or icsi exclusion criteria: * irregular cycles * oocyte donation cycles

Keywords: natural cycle fet spontaneous lh pic hcg